Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2022; 14(12): 2367-2379
Published online Dec 15, 2022. doi: 10.4251/wjgo.v14.i12.2367
Evaluation of short-term effects of drug-loaded microspheres and traditional transcatheter arterial chemoembolization in the treatment of advanced liver cancer
Ting Ye, Shi-Han Shao, Kan Ji, Shu-Lin Yao
Ting Ye, Shu-Lin Yao, Department of Nuclear Medicine, First Medical Center, PLA General Hospital, Beijing 100039, China
Shi-Han Shao, Department of Hepatobiliary Surgery, The Sixth Medical Center, PLA General Hospital, Beijing 100048, China
Kan Ji, Department of Interventional Radiology, First Medical Center, PLA General Hospital, Beijing 100071, China
Author contributions: Ye T contributed to the research design and thesis writing; Shao SH collected and analyzed the data; Ji K contributed to the data collection; Yao SL overall supervise the study; and all authors proofed the revised manuscript.
Supported by National key research and development project of Ministry of Science and Technology, No. 2016YFC0103908.
Institutional review board statement: This study was approved by the First Medical Center, PLA General Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: No conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Shu-Lin Yao, MD, Associate Chief Technician, Statistical Worker, Department of Nuclear Medicine, First Medical Center, PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100039, China.
Received: August 1, 2022
Peer-review started: August 1, 2022
First decision: August 21, 2022
Revised: August 29, 2022
Accepted: November 16, 2022
Article in press: November 16, 2022
Published online: December 15, 2022
Research background

Liver cancer is a malignant tumor with high morbidity and mortality. One of the main reasons is that conventional Transcatheter arterial chemoembolization (TACE) is not a standardized procedure, and there are some differences in the use of embolization materials, selection of chemotherapeutic drugs, and operation techniques among different regions and teams.

Research motivation

This study compared the effect of using the same size of embolization particles and drug-eluting bead (DEB) during TACE. We investigated the effect and systemic response of chemotherapy drugs in TACE under the new local drug delivery mode.

Research objectives

This study aimed to explore the short-term efficacy of drug-loaded microspheres TACE (D-TACE) and traditional TACE in the treatment of advanced liver cancer.

Research methods

The clinical data of 73 patients with advanced liver cancer admitted to the First and Sixth Medical Centers of Chinese PLA General Hospital from January 2017 to October 2019 were retrospectively analyzed.

Research results

There were no statistical differences in the values of glutamic oxalyl transaminase, glutamic alanine transaminase, total bilirubin, serum albumin, leukocytes, red blood cells, and platelets before and after surgery in the drug-laden microsphere group and the conventional TACE group. In the postoperative 24 h postoperative nausea and vomiting score and postoperative pain score, the traditional TACE group was higher than the drug-loaded microsphere group, and the data of the two groups were statistically different.

Research conclusions

The authors found that compared with traditional TACE, D-TACE may have more advantages in the short-term efficacy for treating large hepatocellular carcinoma in the middle and late stages.

Research perspectives

D-TACE is worthy of clinical promotion. However, the long-term prognosis of D-TACE and traditional TACE for patients with advanced liver cancer needs to be further explored in large-sample randomized controlled trials.